Clinical trials: Digestive Cancer
Pancreatic Cancer
Cetuximab, Radiotherapy and Twice Weekly Gemcitabine to Treat Pancreatic Cancer
This study is designed to establish the safety and efficacy of a combination of Erbitux (cetuximab)/Gemzar (gemcitabine)/radiation in patients with pancreatic cancer.
- Trial name
- NCT00225784
- Testing
- Cetuximab/Gemcitabine, Radiotherapy
- Volunteers
- 37 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Hepatocellular Carcinoma, Liver Metastases
Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy
This is an open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of STP705 administered intratumorally in cholangiocarcinoma, hepatocellular carcinoma…
- Conditions
- Hepatocellular Carcinoma, Liver Metastases, Cholangiocarcinoma
- Trial name
- NCT04676633
- Testing
- STP705
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Sirnaomics
Adenocarcinoma
Safety and Efficacy Therapy of Gemcitabine and Erbitux® to R0 or R1 Resected Pancreatic Cancer
This is an open-label, non-randomized Phase II study to evaluate immunochemotherapy in patients with R0 OR R1-resected pancreatic cancer.
- Trial name
- ATIP (NCT00395252)
- Testing
- Cetuximab (Erbitux®) and Gemcitabine
- Where
- 8 sites in Germany
- Volunteers
- 76 people
- Sponsor
- Carmen Schade-Brittinger
Artificial Intelligence, Deep Learning
Development and Demonstration of Intelligent Assessment Based on Multi-modal Information Fusion for Tumor Risk and Diagnosis and Treatment
To improve the accuracy of risk prediction, screening and treatment outcome of cancer, we aim to establish a medical database that includes standardized and structured clinical diagnosis and treatment information, image features…
- Conditions
- Artificial Intelligence, Deep Learning, Lung Cancer, Lung; Node
- Trial name
- NCT06653478
- Testing
- No Intervention
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Hepatocellular Carcinoma (HCC)
A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma
This is a multicenter, randomized, double-blind, parallel-controlled integrated phase I/III clinical study to evaluate the efficacy, safety, PK, and immunogenicity of HLX13 and YERVOY® in patients with unresectable hepatocellular…
- Trial name
- NCT06841185
- Testing
- HLX13, US-sourced YERVOY®, EU-sourced YERVOY®
- Volunteers
- 656 people
- Sponsor
- Shanghai Henlius Biotech
Colorectal Neoplasms
Metastatic Colorectal Cancer Patients With Long-term Response to Regorafenib
The aim of this local NIS(Non-Interventional Study) is to determine the proportion of Belgian patients with a duration of treatment(DoT) to Stivarga of 4 months or more in relation to the total population of Belgian metastatic…
- Trial name
- COLONG (NCT03386825)
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- Belgium
- Volunteers
- 76 people
- Sponsor
- Bayer
Colorectal Cancer, Indocyanine Green
Endoscopic Submucosal Injection of Indocyanine Green Before Laparoscopic Radical Resection for Colorectal Cancer
Prospective registry study of endoscopic submucosal injection of indocyanine green before laparoscopic radical resection for colorectal cancer
- Trial name
- NCT04207489
- Testing
- endoscopic submucosal injection of indocyanine green before laparoscopic radical operation of colorectal cancer
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Jilin University
Hepatocellular Carcinoma
A Prospective, Multicenter, Phase II Clinical Study on the Treatment of Unresectable Advanced HCC with DEB-TACE Combined with SALOX-HAIC
The aim of this study is to clarify the safety and efficacy of DEB-TACE combined with SALOX-HAIC in the treatment of unresectable advanced primary liver cancer.
- Trial name
- NCT06823050
- Where
- 7 sites in China
- Volunteers
- 59 people
- Sponsor
- Xuhua Duan
Hepatocellular Carcinoma
Safety and Efficacy Study of Lenvatinib Combined With VIC-1911 for the Treatment of Advanced HCC
This study is a single-arm, open-label trial to clarify the safety and efficacy of the combined treatment of lenvatinib and VIC-1911 in patients with advanced liver cancer.
- Trial name
- NCT06519721
- Testing
- Lenvatinib Combined with VIC-1911
- Where
- China
- Volunteers
- 12 people
- Sponsor
- RenJi Hospital
Metastatic Colorectal Cancer
A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab
This study is a prospective, multi-arm, phase II clinical trial that uses transcriptome profiling to guide the evaluation of the efficacy of multiple lines of standard chemotherapy and bevacizumab combined with adebrelimab in…
- Trial name
- NCT06513221
- Testing
- Chemotherapy, Bevacizumab, Adebrelimab
- Volunteers
- 100 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma, Hepatoma
Accuracy of Endoscopic Ultrasound for Detection of Tumors of the Liver
The diagnostic accuracy of EUS for detection of the liver tumors (primary and metastatic) remains unknown. To compare the accuracy of the EUS and CT scan for detection of the primary and metastatic carcinoma of the liver.
- Conditions
- Hepatocellular Carcinoma, Hepatoma, Cholangiocarcinoma, Liver Metastases
- Trial name
- NCT00290316
- Testing
- Endoscopy ultrasound
- Where
- United States
- Sponsor
- Central Texas Veterans Health Care System
Hepatocellular Carcinoma, Cirrhosis
Circulating Cell-free DNA-based Epigenetic Biomarker mSEPT9 for Hepatocellular Carcinoma Detection in Cirrhosis
Brief Summary (Plain-Language Version - Compliant with ClinicalTrials.gov Guidelines) The goal of this observational study is to learn whether a blood test called methylated SEPT9 (mSEPT9) can help diagnose hepatocellular…
- Trial name
- SEPT9_CROSS (NCT03311152)
- Testing
- "Epi proColon 2.0 CE" test from Epigenomics, Inc (Berlin, Germany)
- Where
- France
- Volunteers
- 639 people
- Sponsor
- Central Hospital, Nancy, France
Vitamin D on Tumor Response and Inflammatory Markers, Colo-rectal Cancer
Evaluation the of Role of Vitamin D Supplement on Tumor Response, Inflammation and Apoptosis in Patients With Stage II or III Colorectal Cancer Receiving Chemotherapy.
The aim of this work is to assess the of role of Vitamin D supplement on tumor response, inflammation and apoptosis in patients with stage II or III colorectal cancer receiving chemotherapy using BAX protein and Tumor necrosis…
- Trial name
- NCT07241247
- Testing
- Vitamin D
- Where
- Egypt
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Tanta University
Pancreatic Neoplasm
Cancer Stem Cell Specific Aptamer's Ability to Detect Blood Circulating Cancer Stem Cells and Its Role as a Predictor of Prognosis in Pancreatic Cancer
The treatment performance of pancreatic cancer has not changed significantly over the past 20 years and is still less than 10%. In addition, 80-90% of pancreatic cancer patients are found to be already advanced at the time of…
- Trial name
- NCT05745415
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Yonsei University
Esophageal Cancer, Recurrent Laryngeal Nerve
The Value of Near-Infrared Fluorescence Imaging in the Protection of the Recurrent Laryngeal Nerve During Minimally Invasive Esophagectomy
The goal of this clinical trial is to learn whether the application of indocyanine green near-infrared imaging system can accurately locate the recurrent laryngeal nerve (RLN) during lymph node dissection in esophageal cancer…
- Conditions
- Esophageal Cancer, Recurrent Laryngeal Nerve, ICG (Indocyanine Green), Lymph Node Dissection
- Trial name
- NCT07406815
- Testing
- ICG (Indocyanine Green)
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Fujian Medical University Union Hospital
Metastatic Colorectal Carcinoma
A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer
This is a multicenter, open label Phase 1b/2 study in patients with metastatic colorectal carcinoma. The Phase 1b will identify the dose of the combination of PF-05212384 plus FOLFIRI.
- Trial name
- NCT01937715
- Testing
- PF-05212384, FOLFIRI regimen, Bevacizumab
- Where
- 39 sites in United States, Canada and 1 more
- Volunteers
- 18 people
- Sponsor
- Pfizer
Colorectal Cancer
Azacitidine and CAPOX in Metastatic Colorectal Cancer
The goal of the Phase I portion of this study is to find the highest tolerable dose of azacitidine combined with capecitabine and oxaliplatin (CAPOX) that can be given to patients with metastatic colorectal cancer.
- Trial name
- NCT01193517
- Testing
- Azacitidine, Capecitabine, Oxaliplatin
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- M.D. Anderson Cancer Center
Dysbiosis, Sarcopenia
Bacterial Intestinal Gut Modification Around Cancer Surgery (BIG MACS) Diet
The long-term study objective is to develop optimized nutritional therapies for surgery and test them in clinical practice. This pilot study will test a microbiome-optimization diet in colorectal cancer surgery patients.
- Conditions
- Dysbiosis, Sarcopenia, Colon Cancer
- Trial name
- NCT05658263
- Testing
- Standard Diet, BIG MACS Diet
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Minnesota
Hepatocholangiocarcinoma, Fibrolamellar Carcinoma
A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers
The aim of this French multicenter retrospective study is to describ rare primary hepatic cancers clinical, histological and radiological features, to obtain a biological tumor and blood collection, and to evaluate the efficacy…
- Conditions
- Hepatocholangiocarcinoma, Fibrolamellar Carcinoma, Hepatic Epithelioid Hemangioendothelioma, Hepatoblastoma
- Trial name
- FFCD-2205 (NCT06541652)
- Where
- 40 sites in France
- Volunteers
- 150 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Bile Duct Cancer, Cholangiocarcinoma
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
This trial is designed to study a combination of interventions (chemotherapy, immunotherapy, and radiation) as a potential new treatment for bile duct cancer that cannot be removed with surgery.
- Conditions
- Bile Duct Cancer, Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic
- Trial name
- NCT05655949
- Testing
- Gemcitabine, Cisplatin, Durvalumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Beth Israel Deaconess Medical Center